Working Group Scope
Although Risk Based Monitoring is no longer considered a new way of working, it continues to stay an area that is constantly evolving. Changes in landscape due to the pandemic are accelerating this evolution.
This Working Group will identify innovative approaches in risk management and data analytics to proactively manage data quality and subject safety risks. The Working Group will support the pharmaceutical industry with change management challenges related to moving towards risk-based approaches.
Jeremy Howells: Working Group Lead
Jeremy Howells is a People & Product Leader in the Data Strategy & Delivery, Data Sciences group at Roche. Jeremy has a BSc in Maths from Cardiff University and 15+ years’ experience as a stats programmer. His career in pharmaceutical biometrics began at GlaxoSmithKline in 2006 as a placement statistician. He joined Roche in 2012 as a statistical programmer, working for about seven years across the lifecycle of drug development. In 2019 he made the move into clinical data management as a People Manager, evolving into his current role in 2021. It was here he began his current involvement in risk-based quality management as the Product Operational Expert for QTLs at Roche. Jeremy is a member of the PHUSE QTL Working Group project.
Michael Walega: Working Group Lead
Michael Walega is the Head of Centralized Monitoring at BMS. He is responsible for providing protocol teams with actionable insights to achieve higher quality, ensuring centralised monitoring processes are aligned to relevant regulatory requirements, and championing risk-based quality management approaches to clinical trial monitoring activities.
He was previously at LabCorp/Covance, where he led the team responsible for development and growth of Covance’s Risk-Based Monitoring (RBM) solutions, processes and operational delivery. He also led the Late-Stage Biostatistics and Programming groups, as well as the Process Excellence team. Michael is a qualified biostatistician and a Six Sigma Master Black Belt.